Table 4.

In vivo studies for anti-DLL4 IgG1 mAb.

Species	Study	Dose/s	Group sex and size	Findings
Sprague Dawley rat	8 week GLP toxicology	0 mg/kg (iv)	10M+10F/group and 5M+5F recovery/group and 6M+6F TK satellites/group	Liver findings: Hepatic centrilobular to bridging sinusoidal dilation
		1 mg/kg (iv)		Decreased red blood cells (monitorable)
		3 mg/kg (iv)		Proliferative vascular neoplasms
		10 mg/kg (iv)		– Skin, lung, and heart lesions seen only in rats
		30 mg/kg (iv)
Cynomolgus monkey	8 week GLP toxicology with 12 week recovery	0 mg/kg (iv)	3M+3F/group and 2M+2F recovery/group and 2M+2F for telemetry on the control and high dose group	Liver findings: Hepatic centrilobular to bridging sinusoidal dilation
		0.2 mg/kg (iv)		Decreased red blood cells (monitorable)
		0.8 mg/kg (iv)
		3 mg/kg (iv)
		12 mg/kg (iv)